Weekly Meeting Oct 9 2025

Summary of Weekly Meeting Oct 9, 2025

---

Company Strategy & Operations

Mass Tort Lawsuit Initiative

• The company is actively encouraging patients to join a mass tort lawsuit related to the opioid crisis.
• The lawsuit is positioned as the primary effective tool to combat opioid-related deaths, given governmental agencies (CDC, HHS, FDA) are seen as ineffective or part of the problem.
• Target group: survivors of opioid addiction (estimated 8-9 million affected, with over 4 million deceased).
• Call to action: Patients are urged to sign up and engage, with direct contact options (cell phone, email) provided by leadership.
• Moral framing emphasizes collective responsibility:

  “Are we our brother’s keepers?” The bravery of participants is commended.

Educational Content & Communication

• Launching a book titled “The Pharmaceutical Genocide: The Open Opioid Poisoning Exposed” as a key educational and advocacy tool.
• The book aims to clarify legal standing and strengthen the mass tort case.
• Weekly podcasts (Monday–Thursday, 2:30 PM) provide scientific updates and ongoing education.
• Leadership encourages feedback and interaction regarding the book cover and content.

---

Product & Process: Drug Screening Program

Drug Screen Submission Requirements & AI Integration

• Drug screens must include:
  • A dated test (date must be written directly on the test, not on a note or next to it).
  • Patient’s name on the test.
  • Patient’s valid photo ID (driver’s license) clearly visible in the submission photo.
• Starting November 1, the AI system will automatically reject any drug screen submissions missing these elements.
• The AI compares new submissions to previous ones to detect duplicates or fraud, marking identical tests with visual alerts for manual review.
• Compliance is critical to avoid delays or rejection of prescriptions.

Test Types & Logistics

• Standard test: 6-panel drug screen including:
  • BUP (buprenorphine)
  • Benzo (benzodiazepines)
  • COC (cocaine)
  • MOP (morphine/opioids)
  • MTD (methadone)
  • OX (oxycodone)
• 12-panel tests are available but not stocked by the company; patients must procure these independently if needed.
• 12-panel tests often ship faster than 6-panel tests on Amazon.
• The company offers to ship 6-panel tests directly to patients (primarily in Florida, North Carolina, Tennessee) with 3-day ground shipping and tracking.
• Payment for shipped tests is via Cash App, integrated directly with the postage system for efficiency.
• Leadership encourages patients to reach out if financial hardship prevents obtaining tests; assistance will be provided.

---

Management & Leadership

Patient Advocacy & Support

• Susie Burming, Managing Director and pastor, emphasizes her dual role as manager and patient advocate.
• She maintains open communication channels and offers emotional and spiritual support to patients.
• Patients are encouraged to be proactive champions of their own care while assured of ongoing company support.
• Successes highlighted include couples recovering together and healthy births, reinforcing program impact since 2018.

Community Building & Engagement

• The company fosters a supportive patient community via a Facebook group and regular communications.
• Leadership promotes positivity, mutual support, and “paying it forward” as core cultural values.
• Regular reminders encourage patients to stay on track with their recovery and compliance.

---

Key Frameworks, Processes & Playbooks

• Mass Tort Lawsuit Strategy Positioning legal action as a primary lever for systemic change, supported by educational materials (book, podcasts) and direct patient engagement.

• AI-Enabled Compliance Monitoring Automated verification of drug screens to ensure accuracy and prevent fraud, with clear submission guidelines communicated to patients.

• Patient Support & Retention Multi-channel support (phone, email, text, social media), emotional/spiritual care integrated with clinical management, and financial assistance for compliance-related costs.

---

Metrics & Targets

• No explicit numeric KPIs or financial targets were mentioned.
• Timeline: AI enforcement of drug screen submission rules begins November 1, 2025.
• Program longevity: Operating since 2018 with ongoing patient recovery success stories.

---

Actionable Recommendations

For Patients

• Join the mass tort lawsuit by contacting leadership directly.
• Read and provide feedback on the upcoming book to strengthen advocacy.
• Submit drug screens strictly following the new AI-compliance guidelines to avoid rejection.
• Reach out proactively for financial or emotional support if needed.
• Engage with community resources (podcasts, Facebook group) for education and encouragement.

For Staff

• Continue promoting the mass tort initiative and educational content.
• Monitor AI reports on drug screen submissions and provide timely feedback.
• Facilitate logistics for shipping drug tests efficiently.

---

Presenters & Sources

• Susie Burming – Managing Director, Patient Advocate, and Pastor
• Dr. Smith – Medical Expert and Legal Advocate for Mass Tort Lawsuit

---

This summary focuses on the business execution aspects of patient management, legal strategy, product/process compliance, and leadership engagement highlighted in the meeting.